



EN

ANA HEp-2

REF FA2500A

IVD

Rx Only



## INTENDED USE

ANA HEp-2 is an indirect immunofluorescence assay for the qualitative detection and semi-quantitative determination of IgG anti-nuclear antibodies in human serum by manual fluorescence microscopy or with diFine® automated microscope. The presence of anti-nuclear antibodies can be used in conjunction with other serological tests and clinical findings to aid in the diagnosis of systemic lupus erythematosus and other systemic rheumatic diseases.

## SUMMARY AND EXPLANATION

The indirect immunofluorescence assay (IFA) has been used extensively for detecting the presence of antinuclear antibody (ANA) in the sera of patients with systemic lupus erythematosus (SLE), and other clinically similar connective tissue disorders (1 - 5). In addition, ANA may be associated with numerous drug-induced lupus syndromes (6 - 7) which clinically mimic the spontaneous form of SLE. The IFA technique was adapted to ANA testing by several investigators (8 - 9) following the basic methods originally described by Coons (10). ANA are primarily composed of IgG antibodies; however, IgA and IgM ANA may also be detected (11). It is now recognized that many sources of nuclear material may be employed as a substrate for ANA testing. Although most of the original ANA research was performed using rat or mouse liver or kidney tissue section substrate, the use of human or animal embryonic tissue cell culture substrates has provided a reliable and easy to interpret alternative substrate for ANA testing. The HEp-2 cell line is derived from a human larynx epidermal carcinoma. The use of the HEp-2 cells substrate in IFA increased the sensitivity of the autoantibodies detection and contributed to the diagnosis of systemic autoimmune diseases and the description of new ones, thanks to the possibility of detecting over 100 antigens in their nucleus and cytoplasm. There are several different patterns of nuclear and cytoplasmic immunofluorescence. **diFine® has been programmed to suggest eight common ANA patterns. These eight patterns and the basis for them can be evaluated by diFine® and manual reader are as follows:**

- Homogeneous (AC-1)** - Homogeneous or diffuse staining patterns of the nucleus is consistent with autoantibodies to native DNA (nDNA) histones and/or deoxyribonucleoprotein (DNP) (12, 13). The chromosomes of the mitotic cells (dividing cells) are important indicators of a homogeneous pattern because they will stain as irregularly shaped masses with more intensely stained outer edge.
- Speckled (AC-2, AC-4, and AC-5)** - The speckled pattern is the most commonly observed ANA pattern. A uniform "true speckled" pattern may be seen with centromere antibodies in cells not in division. A dense speckled pattern may be seen with antibodies to n-RNP, Sm, and SSB/La.

*Fine speckled pattern, chromosome-negative (AC-4):* Numerous small and uniform points of fluorescence uniformly scattered throughout the nucleus. The nucleoli will generally appear unstained. The mitotic cells may demonstrate a few speckles in their cytoplasm, but the chromosomes will be negative.

*Coarse speckled pattern, chromosome-negative (AC-5):* Medium-sized points of fluorescence will be scattered throughout the nuclei with distinct nuclear margins. Larger-sized points of fluorescence may also be observed; however, they are too numerous and variable in size to be identified as a nucleolar pattern. The chromosomes in the mitotic cells will be negative.

*Nuclear dense fine speckled (AC-2):* Numerous fine speckles with a dense distribution in the nucleus, excluding nucleoli. Associated with anti-DFS70 antibodies, which may occur in healthy individuals and have limited autoimmune disease implications. Harmon, et al (17) demonstrated that serum samples containing highly monospecific anti-SSA/Ro gave an IF-ANA test pattern of discrete nuclear speckles on a wide variety of human cells and tumor nuclei. Such serum samples with monospecific anti-SSA/Ro produced very little cytoplasmic staining of substrate cells. A distinct, large, variable speckled pattern of 3 to 10 large speckles in the nucleus has been described. These patients with large, variable speckles have undifferentiated rheumatic disease syndromes with IgM ant histone FH-3 antibody (18).
- Centromere (AC-3)** - *Discrete speckled, chromosome (centromere specificity) positive:* The chromosomes will be positive in mitotic cells; in fact, the discrete speckles will only be clustered in the chromosome mass clearly demonstrating the various stages of mitosis. The centromere pattern has been recognized to be associated with the CREST syndrome, which is a milder variant of progressive systemic sclerosis (PSS). The centromere pattern will demonstrate discrete and uniform points of fluorescent speckles scattered throughout the nucleus. Mitotic cells will be positive, demonstrating a clustering of the centromeres in the chromosomes in different arrangements according to the mitotic stage.
- Homogeneous nucleolar (AC-8)** - The nucleolar pattern demonstrates a homogeneous or speckled staining of the nucleolus. This pattern is often associated with a dull, homogeneous fluorescence in the rest of the nucleus. The chromosomes in the mitotic cells are negative. The nucleolar pattern suggests autoantibodies to PM/Scl-75, PM/Scl-100, Th/To, B23/nucleophosmin, nucleolin, No55/SC65. The nucleolar fluorescence will appear as homogeneous, clumped, or speckled, depending on the antigen to which the

autoantibody reacts. Anti nucleolar antibodies occur primarily in the sera of patients with scleroderma, systemic lupus erythematosus, Sjögren's syndrome, or Raynaud's phenomenon (19).

5. **Multiple nuclear Dots (AC-6)** – A small number of nuclear dots ranging from 6 to 20 are most commonly associated with primary biliary cholangitis.
6. **Nuclear Membrane (AC-11)** – *Antinuclear membrane (nuclear laminae)*: The antinuclear membrane pattern appears as a rim around the nucleus and resembles a rim pattern; however, it is distinguished from the rim pattern by the fact that the metaphase chromosome stage is negative. This autoantibody is important to report because it is recognized to be associated with autoimmune liver disease.
7. **Cytoplasmic (Ribosomal) (AC-19)**– The ribosomal pattern is characterized by numerous cytoplasmic speckles with the highest concentration around the nucleus. It is distinguished from the mitochondrial pattern because of the smaller specks and higher density. The significance of the pattern is unknown.
8. **Cytoplasmic (Mitochondrial) (AC-21)** – The pattern will characteristically have numerous cytoplasmic speckles with the highest concentration in the peri-nuclear area. The pattern can be observed in interphase and mitotic cells. The clinical significance of AMA is most frequently an association with primary biliary cholangitis, especially when the AMA is a high titer.

**The additional patterns listed below cannot be identified using diFine® and must be interpreted by a trained operator, in accordance with ICAP nomenclature standards.**

#### **Additional Nuclear Patterns**

1. **Proliferating cell nuclear antigen (PCNA) pattern (AC-13)**: The proliferating cell nuclear antigen pattern is observed as a fine to coarse nuclear speckling in 30 – 60% of the cells in interphase, and a negative staining of the chromosome region of mitotic cells. The PCNA is specific for patients with SLE but not detected in other connective tissue disease disorders.
2. **Centriole pattern (AC-24)**: The centriole pattern is characterized by two distinct points of fluorescence in the nucleus of the mitotic cells or one distinct point of fluorescence in the resting cell. The significance of this pattern is not known; however, it has been observed in PSS.
3. **Spindle fiber pattern (AC-25)**: *Chromosome-positive*: The spindle fiber pattern is unique to cells undergoing mitosis where only the spindle apparatus fluoresces. This pattern has a “spider web” appearance extending from the centriole to the centromeres. The pattern is suggestive of autoantibodies to the microtubules and its significance is unclear.
4. **Midbody pattern (AC-27)**: The midbody pattern is a densely staining region near the cleavage furrow of telophase cells, that is, in the area where the two daughter cells separate. The clinical significance of the pattern is unknown; however, the pattern has been recognized in selected patients with systemic sclerosis.

#### **Additional Cytoplasmic Patterns**

1. *Cytoplasmic fibrillar linear-actin like (AC-15)*: The cytoskeletal pattern is characterized by a distinct “spider web” or fibrous appearance throughout the cell. It has been reported to be associated with autoimmune liver disease (anti-smooth muscle).
2. *Lysosomal pattern (AC-18)*: The lysosomal pattern is observed as a few discrete speckles sparsely spaced throughout the cytoplasm. The pattern is observed in the cytoplasm of interphase and mitotic cells. The clinical significance is unknown.
3. *Polar/Golgi-like (AC-22)*: The golgi apparatus pattern is characterized by positive cytoplasmic staining that is concentrated on only one side of the perinuclear region. The clinical significance is uncertain, but reports in the literature have suggested an association with SLE and Sjögren's Syndrome.

### **PRINCIPLE OF THE ASSAY**

The ANA HEP-2 is designed to detect the presence of circulating ANA in human sera. The assay employs tissue cell culture substrate and goat anti-human immunoglobulin adjusted for optimum use and free of nonspecific background staining. The reaction occurs in two steps:

1. Step one is the sample incubation where any ANA present in the patient sample may bind to the cell substrate, forming an antigen-antibody complex. Other serum components are subsequently washed away.
2. Step two is the conjugate incubation where the anti-human immunoglobulin labeled with FITC is allowed to react with any human immunoglobulin that bound to the substrate during the sample incubation. This will form a stable antigen-antibody-conjugate complex at the location where the initial patient antibody bound to the cell substrate. Excess conjugate is subsequently washed away. The results of the assay can be visualized using a properly equipped fluorescent microscope or diFine®. Any positive reactions will appear as apple-green fluorescent staining within the cell. If the sample had no specific ANA, there will be no distinct nuclear staining of the cell.

## REAGENTS

### Materials Provided:

Each kit contains the following components in sufficient quantities to perform the number of tests indicated on the packaging label.

**NOTE: Conjugate and controls contain a combination of Proclin (0.05% v/v) and Sodium Azide (<0.1% w/v) as preservatives. Zorba-NS® contains Sodium Azide (<0.1% w/v) as a preservative.**

|                       |   |   |
|-----------------------|---|---|
| <b>SLD</b>            | 1 | ANA HEp-2 Substrate Slides: Twenty, 12-well Slides with absorbent blotter and desiccant pouch.  |
| <b>CONJ</b>           | 2 | Conjugate: Goat anti-human IgG labeled with fluorescein isothiocyanate (FITC). Contains phosphate buffer with BSA and counterstain. Three amber bottles, containing 3.5mL. Ready to use.  |
| <b>CTRL</b> +         | 3 | ANA (Homogeneous) Positive Control (Human Serum): Will produce positive apple-green, homogeneous, staining of the cell nucleus. One, 0.5mL, red-capped, vial. Ready to use.   |
| <b>CTRL</b> -         | 4 | Negative Control (Human Serum): Will produce no detectable nuclear staining. One, 0.5mL, green-capped, vial. Ready to use.  |
| <b>DIL</b> <b>SPE</b> | 5 | Zorba-NS® Sample Diluent: Four, 25mL, green-capped, bottles. Ready to use.  |
| <b>BUF</b> <b>PBS</b> | 6 | Phosphate-buffered-saline (PBS): pH 7.2 ± 0.2. Empty contents of each buffer packet into one liter of distilled or deionized water. Mix until all salts are thoroughly dissolved. four packets, sufficient to prepare 4 liters. |
| <b>MNTMED</b>         | 7 | Mounting Media (Buffered Glycerol): Two, 3.0 ml white capped, dripper tripper vials.  |
| <b>COVGLS</b>         | 8 | Cover glass. Package of Twenty-Four, 24 x 60 mm, Thickness #1.  |



### NOTES:

- The following components are not Kit Lot Number dependent and may be used interchangeably with the Sebia IFA Kits, as long as the product numbers are identical: Zorba-NS® (Product Number: FA025S), Mounting Media (Product Number: FA0009S), PBS (Product Number: 0008S), and Cover Glass (product number: S8008)

### MATERIALS REQUIRED BUT NOT PROVIDED

- dIFine® automated microscope or a properly equipped fluorescence microscope.
- Pipettor(s) capable of pipetting volumes between 10 and 200 uL.
- Disposable pipette tips.
- Small test tubes, dilution plate or similar for preparing sample dilutions.
- Slide Washer, or a large staining dish with a magnetic stir plate for washing slides between incubation steps.
- Distilled or deionized water.
- 1 Liter Graduated Cylinder.
- Laboratory timer to monitor incubation steps.
- Disposal basin, disposable gloves, and disinfectant (i.e.: 10% household bleach – 0.5% Sodium Hypochlorite).

### STORAGE CONDITIONS

|  |  |
|--|--|
|  2°C - 8°C  | Unopened Kit.  |
|  | Mounting Media, Conjugate, Slides, Zorba-NS®, Slides*, Positive and Negative Controls. |
|  | Rehydrated PBS (Stable for 30 days).   |
|  2°C - 25°C                                       | Phosphate-buffered-saline (PBS) Packets.   |
| *Once opened, slides must be used that day. Other ready-to-use reagents, except PBS, may be used until their stated expiration date. |  |

## PRECAUTIONS

1. For *In Vitro* diagnostic use.
2. Follow normal precautions exercised in handling laboratory reagents. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves, and eye/face protection. Do not breathe vapor. Dispose of waste observing all local, state, and federal laws.
3. The wells of the slide do not contain viable organisms. However, consider the slide **potentially bio-hazardous materials** and handle accordingly.
4. The controls are **potentially bio-hazardous materials**. Source materials from which these products were derived were found negative for HIV-1 antigen, HBsAg and for antibodies against HCV and HIV by approved test methods. However, since no test method can offer complete assurance that infectious agents are absent, these products should be handled at the Bio-safety Level 2 as recommended for any potentially infectious human serum or blood specimen in the centers for disease control/national institutes of health manual "Biosafety in Microbiological and Biomedical Laboratories": current edition; and OSHA's Standard for Bloodborne Pathogens (20).
5. Adherence to the specified time and temperature of incubations is essential for accurate results. **All reagents must be allowed to reach room temperature (20 - 25°C) before starting the assay**. Return unused reagents to their original containers immediately and follow storage requirements.
6. Improper washing could cause false positive or false negative results. Be sure to minimize the amount of any residual PBS, by blotting, before adding conjugate. Do not allow the wells to dry out between incubations.
7. The conjugate, Zorba NS® and controls contain Sodium azide at a concentration of <0.1% (w/v). Sodium azide has been reported to form lead or copper azides in laboratory plumbing which may cause explosions on hammering. To prevent, rinse sink thoroughly with water after disposing of solution containing Sodium Azide. This preservative may be toxic if ingested.
8. Dilution or adulteration of these reagents may generate erroneous results.
9. Never pipette by mouth. Avoid contact of reagents and patient specimens with skin and mucous membranes.
10. Avoid microbial contamination of reagents. Incorrect results may occur.
11. Cross contamination of reagents and/or samples could cause erroneous results.
12. Reusable glassware must be washed and thoroughly rinsed free of all detergents.
13. Avoid splashing or generation of aerosols.
14. Do not expose reagents to strong light during storage or incubation.
15. Allowing the slide packet to equilibrate to room temperature prior to opening the protective envelope will protect the wells and blotter from condensation.
16. Collect the wash solution in a disposal basin. Treat the waste solution with disinfectant (i.e.:10% household bleach - 0.5% Sodium Hypochlorite). Avoid exposure of reagents to bleach fumes.
17. Do not expose any of the reactive reagents to bleach-containing solutions or to any strong odors from bleach-containing solutions. Trace amounts of bleach (Sodium Hypochlorite) may destroy the biological activity of many of the reactive reagents within this Kit.
18. Do not apply pressure to slide envelope. This may damage the substrate.
19. The components of this Kit are matched for optimum sensitivity and reproducibility. Reagents from other manufacturers should not be interchanged. Follow Package Insert carefully.
20. Unopened/opened components are stable until the expiration date printed on the label, provided the recommended storage conditions are strictly followed. Do not use beyond the expiration date. Do not freeze.
21. Evans blue counterstain is a potential carcinogen. If skin contact occurs, flush with water. Dispose of according to local regulations.
22. Do not allow slides to dry during the procedure. Depending upon lab conditions, it may be necessary to place slides in a moist chamber during incubations.

## SPECIMEN COLLECTION

1. Carry out specimen collection in accordance with CLSI document M29: Protection of Laboratory Workers from Occupationally Acquired Infectious Diseases. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, all blood derivatives should be considered potentially infectious.
2. Only freshly drawn and properly refrigerated sera obtained by approved aseptic venipuncture procedures with this assay (30, 31). No anticoagulants or preservatives should be added. Avoid using hemolyzed, lipemic, or bacterially contaminated sera.
3. Store sample at room temperature for no longer than 8 hours. If testing is not performed within 8 hours, sera may be stored between 2 - 8°C, for no longer than 48 hours. If delay in testing is anticipated, store test sera at -20°C or lower. Avoid multiple freeze/thaw cycles which may cause loss of antibody activity and give erroneous results. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine stability criteria for its laboratory (38).

## ASSAY PROCEDURE

1. Remove slides from refrigerated storage and allow them to warm to room temperature (20 – 25°C). Tear open the protective envelope and remove slides. **Do not apply pressure to flat sides of protective envelope.**
2. Identify each well with the appropriate patient sera and controls. **NOTE: The controls are intended to be used undiluted.** Prepare a 1:40 dilution (e.g.: 10µL of serum + 390µL of Zorba-NS®) of each patient serum.

### Dilution Options:

- a. Users may titrate the Positive control to endpoint to serve as a semi-quantitative (1+ Minimally Reactive) control. In such cases, the control should be diluted two-fold in PBS, **not Zorba-NS®**. An endpoint dilution is established and printed on the Positive Control vial (± one dilution). It should be noted that due to variations within the laboratory (equipment, etc.), each laboratory should establish its own expected end-point titer for each lot of Positive control.
- b. When titrating patient specimens, initial dilutions should be prepared in Zorba-NS® and all subsequent dilutions should be prepared in PBS only. **Titrations must not be prepared in Zorba-NS®.**

3. With suitable dispenser (listed above), dispense 20 – 40µL of each control and each diluted patient sera in the appropriate wells.
4. Incubate slides at room temperature (20 – 25°C) for 35±5 minutes.
5. Gently rinse slides with PBS. **Do not direct a stream of PBS into the test wells.**
6. Wash slides for two, five-minute intervals, changing PBS between washes. Slides may soak during each wash for up to five minutes. **NOTE: For those using automated washers, set the washer to wash each well three times with a soak of zero to five minutes.**
7. Remove slides from PBS one at a time. Invert Slide and key wells to holes in blotters provided. Blot slide by wiping the reverse side with an absorbent wipe.

CAUTION: Position the blotter and slide on a hard, flat surface. Blotting on paper towels may destroy the Slide matrix. **Do not allow the slides to dry during the test procedure.**

8. Add 20 – 40µL of conjugate to each well.
9. Repeat steps 4 through 7.
10. Apply 3 – 5 drops of mounting media to each slide (between the wells) and apply the coverslip. Alternatively, one may apply a small amount of mounting media to each well and apply cover glass. Mounting media must be added within two hours of completing the last wash cycle.
11. Examine slides immediately with an appropriate fluorescence microscope. This may be accomplished manually using a traditional fluorescent microscope or with dIFine®. If using dIFine®, please refer to the instrument manual for operating instructions. **It is recommended that slides be examined on the same day as testing.**

### NOTES:

- a. **If it is not possible to view the slides immediately, slides may be stored for up to 48 hours at 2 – 8°C.**
- b. **If slides will not be examined within a 48-hour period, seal coverslip with clear nail polish and store in refrigerator.**

## QUALITY CONTROL

1. Every time the assay is run, a Positive control, and Negative control must be included.
2. It is recommended that the controls be read prior to evaluating the test samples. If the controls do not appear as described, results may be invalid.
  - a. Negative control – characterized by the absence of specific fluorescence and a red, or dull green, background staining of all cells due to counterstain.
  - b. Positive control (homogeneous pattern) – characterized by apple-green fluorescence. The homogeneous staining pattern is a diffused uniform staining of the entire nucleus.
3. Additional controls may be tested according to guidelines or requirements of local, state, and/or federal regulations or accrediting organizations.

### NOTES:

- a. **Non-specific reagent trapping may exist. It is important to adequately wash slides to eliminate false positive results.**
- b. **The intensity of the observed fluorescence may vary with the microscope and filter system used.**
- c. **Non-nuclear staining of the cell substrate may be observed with some human sera.**

## INTERPRETATION OF RESULTS

1. The interpretation of the results depends on the pattern observed, the titer of the autoantibody, and the age of the patient. The elderly, especially women, are prone to develop low-titrated autoantibodies (<1:80) in the absence of clinical autoimmune disease. Experience suggests that a 1:40 dilution is a good dilution to screen for ANA. Low-titer positive results may occur in apparently healthy persons; therefore, the ANA results must always be interpreted in light of the patient's total clinical presentation.
2. Titers less than 1:40 are considered negative.
3. Positive test: A positive reaction is the presence of any pattern of nuclear apple-green staining observed at a 1:40 dilution based on a 1+ to 4+ scale of staining intensity. 1+ is considered a weak reaction and 4+ a strong reaction. All sera positive at 1:40 should be titrated to endpoint dilution. This is accomplished by making 1:40, 1:80, 1:160, etc. serial dilutions of all positives. The endpoint titer is the highest dilution that produces a 1+ positive reaction.
4. Homogeneous patterns with peripheral accentuation are frequently found in sera from patients with SLE.

|   | Disease Most Frequently Found In  | Reference                |
|---|---|--------------------------|
| Homogeneous:<br>High Titer<br>Low Titer | SLE<br>Rheumatoid Arthritis and other diseases  | (3, 8, 9, and 16)<br>(1) |
| Centromere                              | CREST Syndrome variant of PSS   | (27)                     |
| Speckled                                | Scleroderma, Raynaud's Syndrome, Sjögren's Syndrome,<br>Mixed connective tissue disease | (34 - 36)                |
| Nucleolar                               | Scleroderma   | (37)                     |
| Peripheral                              | SLE   | (2, 8, 9, and 16)        |

### LIMITATIONS OF THE ASSAY

1. The ANA HEp-2 is a laboratory diagnostic aid, and its results are not diagnostic by itself. Positive ANA may be found in apparently healthy individuals. It is therefore imperative that ANA results be interpreted in conjunction with other serological tests and clinical findings.
2. SLE patients undergoing steroid therapy may have negative test results (40).
3. Many commonly prescribed drugs may induce ANA (6, 7).
4. One autoantibody pattern may partially or completely obscure the diagnostic features of the other. In such instances, it is necessary to titrate the serum.
5. No definitive association between the pattern of nuclear fluorescence and any specific disease state is intended with this product.

### EXPECTED RESULTS

The expected value in the normal population is negative or less than 1:40. However, apparently healthy individuals may contain ANA in their sera (36). This percentage increases with aging, particularly in the 7th decade of life.

### PERFORMANCE CHARACTERISTICS

**NOTE: When establishing Performance Characteristics of the ANA HEp-2, slides were interpreted using three different methods as outlined below:**

| Interpretation Method:   |
|--|
| <b>Method A.</b> Method A was a completely manual interpretation method. It was accomplished using a traditional fluorescent microscope equipped with objective and ocular lenses. Determining the qualitative outcome and the pattern were accomplished using trained laboratory technicians.   |
| <b>Method B.</b> Method B was accomplished by scanning the slides using dIFine® and subsequently having a trained laboratory technician interpret the resulting digital image (qualitative and pattern if positive) appearing on the computer monitor.   |
| <b>Method C.</b> Method C is the <b>suggested outcome</b> predicted by dIFine®; Method C predicts the qualitative result and, if positive, the pattern if it is one of the eight patterns the system has been programmed to call. If Method C is "UNC" (uncertain), the level of fluorescence measured by dIFine is borderline between positive and negative. Method C must be "validated" or accepted by the laboratory technician or modified or invalidated completely. For purposes of this study and the data presented below, <b>Method C</b> is logged "AS IS" without any modification by the laboratory technician(s). It is therefore presented for <i>informational purposes only</i> . |

### 1. Analytical Performance Studies:

#### a. Linearity:

Strong positive samples were identified for each of the following eight ANA patterns: Homogeneous, Speckled, Centromere, Nucleolar, Nuclear Dots, Nuclear Membrane, Cytoplasmic (Ribosomal) and Cytoplasmic (Mitochondrial). Each of the samples was assayed at 1:40 and titrated to 1:20480 and interpreted by all three methods noted above. This study was conducted internally at ZEUS Scientific. The endpoints for each sample and each method are presented below:

| Sample                      | Method A | Method B | Method C |
|-----------------------------|----------|----------|----------|
| Homogeneous                 | 1:1280   | 1:1280   | 1:1280   |
| Speckled                    | 1:5120   | 1:5120   | 1:2560   |
| Centromere                  | 1:5120   | 1:5120   | 1:5120   |
| Nucleolar                   | 1:2560   | 1:5120   | 1:2560   |
| Nuclear Dots                | 1:640    | 1:640    | 1:640    |
| Nuclear Membrane            | 1:2560   | 1:2560   | 1:2560   |
| Cytoplasmic (Ribosomal)     | 1:320    | 1:320    | 1:320    |
| Cytoplasmic (Mitochondrial) | 1:10240  | 1:10240  | 1:10240  |

Summary: In 100% of the cases, the pattern called was as expected and in agreement regardless of the method of interpretation. Likewise, the endpoint determination was as expected ± one dilution for 100% of the determinations regardless of the method of interpretation.

**b. Lot-to-Lot Reproducibility:**

A moderately positive sample and a strong positive sample were identified for each of the following eight ANA patterns: Homogeneous, Speckled, Centromere, Nucleolar, Nuclear Dots, Nuclear Membrane, Cytoplasmic (Ribosomal) and Cytoplasmic (Mitochondrial). Additionally, nine negative samples were included bringing the total group to 25 specimens. This group of 25 specimens was assayed on three different lots of ANA HEP-2 and interpreted via all three methods noted above. Additionally, all sixteen positive members were titrated to endpoint and interpreted via all three methods.

**Results:**

- i. Qualitative Agreement:** There was 100% agreement in the qualitative results at the screening dilution of all 25 specimens across all three kit lots, and there was 100% agreement across all three interpretation methods regardless of reagent kit lot.
- ii. Endpoint Titer Agreement:** All 16 positive specimens resulted in same endpoint titers ± one dilution regardless of reagent kit lot or method interpretation.
- iii. Pattern Agreement:** For dilutions yielding a positive result across all three interpretation methods, there was 100% pattern agreement for lot one and lot two for all three interpretation methods. For lot three there was 100% pattern agreement between Method A and Method B, with one homogenous mid positive specimen as the only outlier when comparing Method C versus Methods A and B.

**c. Reference Range Study:**

One hundred and eighty random serum samples were acquired from healthy donors in Northeastern US. The samples were assayed at the screening dilution of 1:40 and interpreted via all three methods. Any samples producing a positive result at 1:40 were titrated and interpreted via all three methods. The results of the screening test are summarized below:

| Interpretation Method | Number of Positives | % Positives | Number of Negatives | % Negatives | Number of Uncertain | % Uncertain |
|-----------------------|---------------------|-------------|---------------------|-------------|---------------------|-------------|
| A                     | 19                  | 10.56       | 161                 | 89.44       | NA                  | NA          |
| B                     | 19                  | 10.56       | 161                 | 89.44       | NA                  | NA          |
| C                     | 14                  | 7.78        | 152                 | 84.44       | 14                  | 7.78        |

**d. Twenty-day Repeatability Study:**

A low positive sample (~1:40 endpoint), a mid-positive sample (~1:160 to 1:320 endpoint) and a strong positive sample (≥ 1:640 endpoint) were identified for each of the following eight ANA patterns: Homogeneous, Speckled, Centromere, Nucleolar, Nuclear Dots, Nuclear Membrane, Cytoplasmic (Ribosomal) and Cytoplasmic (Mitochondrial). One ANA negative specimen was also included bringing the group of specimens to a total of 25. These 25 specimens were assayed (1:40 screening dilution) at ZEUS Scientific in triplicate, on ten different days producing 30 results per sample. The slides were interpreted by all three methods. For the within-method evaluation, the results of the qualitative agreement and the pattern agreement are depicted below: there was 100% qualitative agreement in all samples when read using Methods A and B. For Method C, 22 out of 25 specimens showed 100% qualitative agreement; homogenous low positive, nucleolar low positive, and nuclear membrane low positive specimens did not have complete qualitative agreement. Additionally, there was 100% pattern agreement within Methods A and B. For method C, there was 100% pattern agreement for 21 out of 25 specimens with outliers observed in homogenous low positive, nucleolar low positive and nuclear membrane low positive and nuclear membrane high positive specimens.

**Within-Method Qualitative Result Agreement**

| Sample                   | Method A Agreement (95% CI) | Method B Agreement (95% CI) | Method C Agreement (95% CI) |
|--------------------------|-----------------------------|-----------------------------|-----------------------------|
| Homogenous Low Positive  | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 76.7%<br>(59.1 – 88.2%)     |
| Homogenous Mid Positive  | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Homogenous High Positive | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Speckled Low Positive    | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Speckled Mid Positive    | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Speckled High Positive   | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Centromere Low Positive  | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Centromere Mid Positive  | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Centromere High Positive | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |

| <b>Sample</b>                     | <b>Method A Agreement (95% CI)</b> | <b>Method B Agreement (95% CI)</b> | <b>Method C Agreement (95% CI)</b> |
|-----------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Nucleolar<br>Low Positive         | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 96.7%<br>(83.3 – 99.4%)            |
| Nucleolar<br>Mid Positive         | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Nucleolar<br>High Positive        | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Mitochondria<br>Low Positive      | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Mitochondrial<br>Mid Positive     | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Mitochondrial<br>High Positive    | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Nuclear Membrane<br>Low Positive  | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Nuclear Membrane<br>Mid Positive  | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Nuclear Membrane<br>High Positive | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Nuclear Dots<br>Low Positive      | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Nuclear Dots<br>Mid Positive      | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Nuclear Dots<br>High Positive     | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Ribosomal<br>Low Positive         | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Ribosomal<br>Mid Positive         | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Ribosomal<br>High Positive        | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Negative                          | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |

**Within-Method Pattern Result Agreement (Technician 2)**

| <b>Sample</b>               | <b>Method A Agreement (95% CI)</b> | <b>Method B Agreement (95% CI)</b> | <b>Method C Agreement (95% CI)</b> |
|-----------------------------|------------------------------------|------------------------------------|------------------------------------|
| Homogenous<br>Low Positive  | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 73.3%<br>(55.6 – 85.8%)            |
| Homogenous<br>Mid Positive  | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Homogenous<br>High Positive | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Speckled<br>Low Positive    | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Speckled<br>Mid Positive    | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Speckled<br>High Positive   | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Centromere<br>Low Positive  | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Centromere<br>Mid Positive  | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |
| Centromere<br>High Positive | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              | 100%<br>(88.7 – 100%)              |



| Sample                            | Method A Agreement (95% CI) | Method B Agreement (95% CI) | Method C Agreement (95% CI) |
|-----------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Nucleolar<br>Low Positive         | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 96.7%<br>(83.3 – 99.4%)     |
| Nucleolar<br>Mid Positive         | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Nucleolar<br>High Positive        | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Mitochondria<br>Low Positive      | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Mitochondrial<br>Mid Positive     | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Mitochondrial<br>High Positive    | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Nuclear Membrane<br>Low Positive  | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 86.67%<br>(70.3 – 94.7%)    |
| Nuclear Membrane<br>Mid Positive  | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Nuclear Membrane<br>High Positive | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 96.7%<br>(83.3 – 99.4%)     |
| Nuclear Dots<br>Low Positive      | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Nuclear Dots<br>Mid Positive      | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Nuclear Dots<br>High Positive     | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Ribosomal<br>Low Positive         | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Ribosomal<br>Mid Positive         | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |
| Ribosomal<br>High Positive        | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       | 100%<br>(88.7 – 100%)       |

For the between-method agreement, there was 100% qualitative and pattern agreement between Method A versus Method B. However, only 22 out of 25 specimens showed 100% qualitative in the comparisons between Method B vs Method C and Method A vs Method C; the discrepant samples were the homogenous low positive, nucleolar low positive and nuclear membrane low positive specimens. Additionally, only 21 out of 25 specimens showed 100% pattern agreement in the comparisons between Method B vs Method C and Method A vs Method C; the discrepant samples were the homogenous low positive, nucleolar low positive and nuclear membrane low positive and nuclear membrane high positive specimens.

**Between-Method Qualitative Result Agreement**

| Sample                      | Method A vs<br>Method B Agreement<br>(95% CI) | Method A vs<br>Method C Agreement<br>(95% CI) | Method B vs<br>Method C Agreement<br>(95% CI) |
|-----------------------------|---|---|---|
| Homogenous<br>Low Positive  | 100%<br>(88.7 – 100%)                         | 76.67%<br>(59.1 – 88.2%)                      | 76.67%<br>(59.1 – 88.2%)                      |
| Homogenous<br>Mid Positive  | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         |
| Homogenous<br>High Positive | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         |
| Speckled<br>Low Positive    | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         |
| Speckled<br>Mid Positive    | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         |
| Speckled<br>High Positive   | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         |
| Centromere<br>Low Positive  | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         | 100%<br>(88.7 – 100%)                         |

| Sample                         | Method A vs Method B Agreement (95% CI) | Method A vs Method C Agreement (95% CI) | Method B vs Method C Agreement (95% CI) |
|--------------------------------|---|---|---|
| Centromere Mid Positive        | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Centromere High Positive       | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nucleolar Low Positive         | 100%<br>(88.7 – 100%)                   | 96.67%<br>(83.3 – 99.4%)                | 96.67%<br>(83.3–99.4%)                  |
| Nucleolar Mid Positive         | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nucleolar High Positive        | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Mitochondria Low Positive      | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Mitochondrial Mid Positive     | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Mitochondrial High Positive    | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Membrane Low Positive  | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 90%<br>(74.4 – 96.5%)                   |
| Nuclear Membrane Mid Positive  | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Membrane High Positive | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Dots Low Positive      | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Dots Mid Positive      | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Dots High Positive     | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Ribosomal Low Positive         | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Ribosomal Mid Positive         | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Ribosomal High Positive        | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Negative                       | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |

**Between Method Pattern Result Agreement**

| Sample                   | Method A vs Method B Agreement (95% CI) | Method A vs Method C Agreement (95% CI) | Method B vs Method C Agreement (95% CI) |
|--------------------------|---|---|---|
| Homogenous Low Positive  | 100%<br>(88.7 – 100%)                   | 73.3%<br>(55.6 – 85.9%)                 | 73.3%<br>(55.6 – 85.9%)                 |
| Homogenous Mid Positive  | 100%<br>(88.65 – 100%)                  | 100%<br>(88.65 – 100%)                  | 100%<br>(88.7 – 100%)                   |
| Homogenous High Positive | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Speckled Low Positive    | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Speckled Mid Positive    | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Speckled High Positive   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |

| Sample                         | Method A vs Method B Agreement (95% CI) | Method A vs Method C Agreement (95% CI) | Method B vs Method C Agreement (95% CI) |
|--------------------------------|---|---|---|
| Centromere Low Positive        | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Centromere Mid Positive        | 100%<br>(88.65 – 100%)                  | 100%<br>(88.65 – 100%)                  | 100%<br>(88.7 – 100%)                   |
| Centromere High Positive       | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nucleolar Low Positive         | 100%<br>(88.7 – 100%)                   | 96.7%<br>(83.3 - 99.4%)                 | 96.7%<br>(83.3 - 99.4%)                 |
| Nucleolar Mid Positive         | 100%<br>(88.65 – 100%)                  | 100%<br>(88.65 – 100%)                  | 100%<br>(88.7 – 100%)                   |
| Nucleolar High Positive        | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Mitochondria Low Positive      | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Mitochondrial Mid Positive     | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Mitochondrial High Positive    | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Membrane Low Positive  | 100%<br>(88.7 – 100%)                   | 86.7%<br>(70.3 - 94.7)                  | 86.7%<br>(70.3 - 94.7%)                 |
| Nuclear Membrane Mid Positive  | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Membrane High Positive | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 96.7%<br>(83.3 - 99.4%)                 |
| Nuclear Dots Low Positive      | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Dots Mid Positive      | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Nuclear Dots High Positive     | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Ribosomal Low Positive         | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Ribosomal Mid Positive         | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |
| Ribosomal High Positive        | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   | 100%<br>(88.7 – 100%)                   |

**e. Five-day, Multi-Site Reproducibility Study:**

A low positive sample (~1:40 endpoint), a mid-positive sample (~1:160 - 1:320 endpoint) and a strong positive sample ( $\geq$  1:640 endpoint) were identified for each of the following eight ANA patterns: Homogeneous, Speckled, Centromere, Nucleolar, Nuclear Dots, Nuclear Membrane, Cytoplasmic (Ribosomal) and Cytoplasmic (Mitochondrial). One ANA negative specimen was also included bringing the group of specimens to a total of 25. These 25 specimens were assayed (1:40 screening dilution) in triplicate, two times per day on five different days and three different laboratories, producing 30 results per sample, per location. The slides were interpreted by all three methods. At each site, Method A and Method B were also interpreted by two separate laboratory technicians. The results of the qualitative agreement and the pattern agreement are depicted below:

**i. Overall Qualitative Result Agreement**

- a. Within Method:** Within method qualitative agreement for Method A and Method B was 100% for all three sites and all technicians. For Method C, there was 100% agreement for 24 out of 25 specimens at all sites and all technicians: one nuclear membrane low positive specimen being the only discrepant sample at site 2.
- b. Between Method:** There was 100% qualitative agreement for all 25 specimens between Method A versus Method B and Method A versus Method C. Notably, there was 100% qualitative agreement between Method B vs Method C for 24 out of 25 specimens with the nuclear membrane low positive specimen being an outlier at site 2.

**ii. Pattern Result Agreement**

- a. Within Method:** Within method pattern agreement for Method A and Method B was 100% for all three sites and all technicians. For Method C, there was 100% agreement for 24 out of 25 specimens with centromere mid specimen as the only outlier.
- b. Between Method:** There was 100% pattern agreement for all 25 specimens between Method A vs B for all sites and all technicians. For Method A vs Method C, there were two discrepant samples: a centromere mid specimen at Site 1 and nuclear membrane low specimen at Site 2. Similarly, for Method B vs Method C, there were two discrepant samples: a centromere mid specimen at Site 1 and a nuclear membrane low specimen at Site 2

**f. Interference Study:**

A mid-positive sample (~1:160 to 1:320 endpoint) and a strong positive sample ( $\geq$  1:640 endpoint) were identified for each of the following eight ANA patterns: Homogeneous, Speckled, Centromere, Nucleolar, Nuclear Dots, Nuclear Membrane, Cytoplasmic (Ribosomal) and Cytoplasmic (Mitochondrial). One ANA negative specimen was also included bringing the group of specimens to a total of 17. These 17 specimens were spiked with two different concentrations (low spike and high spike) of twelve different possible interferents as outlined in the table below. All specimens were evaluated on the ANA HEp-2 and interpreted by all three methods noted above.

| Interferent        | Interferent Testing Concentrations |            |
|--------------------|------------------------------------|------------|
|                    | Low                                | High       |
| Intralipids        | 3 mg/mL                            | 7.50 mg/mL |
| Cholesterol        | 1.5 mg/mL                          | 2.5 mg/mL  |
| Albumin            | 35 mg/mL                           | 50 mg/mL   |
| Ibuprofen          | 0.5 mg/mL                          | 2 mg/mL    |
| Prednisone         | 0.2 mg/mL                          | 0.8 mg/mL  |
| Hydroxychloroquine | 0.006 mg/mL                        | 0.2 mg/mL  |
| Simvastatin        | 4 ug/mL                            | 20 ug/mL   |
| Cyclophosphamide   | 1 mg/mL                            | 4 mg/mL    |
| Rheumatoid Factor  | 200 U/mL                           | 400 U/mL   |
| Hemoglobin         | 100 mg/mL                          | 200 mg/mL  |
| Triglycerides      | 1.5 mg/mL                          | 5 mg/mL    |
| Bilirubin          | 0.01 mg/mL                         | 0.15 mg/mL |

**Results:** For methods A and B, neither the qualitative agreement or the resulting pattern were affected by the addition of the possible interferents. Method C yielded one uncertain result in a low positive nuclear membrane sample when spiked with Albumin. Therefore, it can be concluded that the results of the ANA HEp-2 are not at significant risk of erroneous results from the presence of the interferents tested.

A second interference study was conducted that focused on the assay cut off and included some additional potential interferents. Samples were selected for each of the eight ANA patterns (Homogeneous, Speckled, Centromere, Nucleolar, Nuclear Dots, Nuclear Membrane, Cytoplasmic (Ribosomal) and Cytoplasmic (Mitochondrial)) that exhibited an endpoint titer of 1:40-1:80 (near the assay cut off) as well as one ANA negative specimen. These nine specimens were spiked at two different concentrations of the interferents as listed below.

| Interferent              | Interferent Testing Concentrations |                |
|--------------------------|------------------------------------|----------------|
|                          | Low                                | High           |
| Bilirubin (unconjugated) | 0.02 mg/mL                         | 0.15 mg/mL     |
| Cholesterol (total)      | 1.5 mg/mL                          | 2.2 mg/mL      |
| Triglycerides            | 1 mg/mL                            | 2.5 mg/mL      |
| Albumin                  | 35 mg/mL                           | 52 mg/mL       |
| Hemoglobin               | 100 mg/mL                          | 200 mg/mL      |
| Intralipids              | 2.0 mg/mL                          | 20 mg/mL       |
| Rheumatoid Factor        | 200 U/mL                           | 400 mg/mL      |
| Cyclophosphamide         | 0.183 mg/mL                        | 0.549 mg/mL    |
| Ibuprofen                | 0.073 mg/mL                        | 0.219 mg/mL    |
| Hydroxychloroquine       | 0.006 mg/mL                        | 0.024 mg/mL    |
| Simvastatin              | 0.0000277 mg/mL                    | 0.000083 mg/mL |
| Prednisone               | 0.000033 mg/mL                     | 0.000099 mg/mL |
| Azathioprine             | 0.00086 mg/mL                      | 0.00258 mg/mL  |
| Diltiazem                | 0.0003 mg/mL                       | 0.0009 mg/mL   |
| Mycophenolate mofetil    | 0.012 mg/mL                        | 0.048 mg/mL    |

|           |           |         |
|-----------|-----------|---------|
| Rituximab | 0.5 mg/mL | 2 mg/mL |
| Belimumab | 2 mg/mL   | 8 mg/mL |

Results: Again, neither the qualitative agreement or the resulting pattern were affected by the addition of the possible interferents, regardless of the method of interpretation. Therefore, it can be concluded that the results of the ANA HEP-2 are not at significant risk of erroneous results from the presence of the interferents tested.

## 2. Clinical Performance Study Design:

A total of 380\* clinically characterized specimens were acquired as outlined in the table below. These 380 specimens were aliquoted and sent to three different laboratories for evaluation by ANA HEP-2. All three labs evaluated the slides via all three methods noted above. Additionally, slide interpretation Method A and Method B were repeated twice at each clinical site by two different laboratory technicians. At each clinical site, the 380 specimens were first screened at a 1:40 dilution for an assessment of the qualitative status of the 380 specimens. Any specimen generating a positive result at the 1:40 screening dilution (for any of the three interpretation methods) was then titrated and interpreted via all three methods again to determine the endpoint as well as the pattern. \* **NOTE: Site two tested a fewer number of Celiac and Vasculitis specimens resulting in a total of 350 specimens at site two.**

Results were used to assess clinical specificity (potential cross reactivity), clinical sensitivity, qualitative agreement between methods within sites, Method C interpretation between sites (i.e., dIFine® to dIFine® automated microscope comparison), endpoint titer agreement and pattern agreement.

| ANA-Associated Diseases                          | n, All Sites | Non-ANA-Associated Diseases       | n, Site 1 and Site 3 | n, Site 2 |
|--|--------------|-----------------------------------|----------------------|-----------|
| <i>Connective Tissue Diseases:</i>               |              | <i>Other Autoimmune Diseases:</i> |                      |           |
| Systemic Lupus Erythematosus (SLE)               | 40           | Celiac Disease                    | 22                   | 10        |
| Sjogren's Syndrome (SS)                          | 30           | ANCA-associated Vasculitis        | 28                   | 10        |
| Scleroderma                                      | 20           | Crohn's Disease                   | 10                   | 10        |
| Autoimmune Myositis (AM)                         | 20           | Rheumatoid Arthritis              | 30                   | 30        |
| Mixed Connective Tissue Disease (MCTD)           | 20           | Autoimmune Thyroiditis            | 30                   | 30        |
| CREST  | 20           | Inflammatory Bowel Disease (IBD)  | 10                   | 10        |
| <i>Other ANA-Associated Autoimmune Diseases:</i> |              | Ulcerative Colitis                | 10                   | 10        |
| Autoimmune Hepatitis (AIH)                       | 20           | <i>Other Diseases:</i>            |                      |           |
| Drug-Induced Lupus (DIL)                         | 20           | Malignancy/Cancer                 | 20                   | 20        |
|  |              | Fibromyalgia                      | 10                   | 10        |
|  |              | Infectious Diseases               | 10                   | 10        |
| <b>Total</b>                                     | 190          | <b>Total</b>                      | 190                  | 160       |

## 3. Clinical Sensitivity and Clinical Specificity:

The clinical sensitivity was calculated at each site on SLE separately, and on the combination of the connective tissue diseases (CTD: SLE+ SS + scleroderma+ CREST+ MCTD+ AM) plus other ANA-associated diseases (autoimmune liver hepatitis + Drug-induced Lupus). Specificity was calculated using the non-ANA-associated diseases total control population.

### a. Clinical Performance at Site 1

| Diagnostic Sensitivity and Specificity |          |              | % Sensitivity (95% CI) | % Sensitivity 95% CI)                   | % Specificity (95% CI)                |
|--|----------|--------------|------------------------|---|---------------------------------------|
|  |          |              | SLE (n = 40)           | CTD + ANA-Associated Diseases (n = 190) | Non-ANA-Associated Diseases (n = 190) |
| Site 1                                 | Method A | Technician A | 52.5% (37.5 - 67.1%)   | 53.2% (46.1 - 60.1%)                    | 75.8% (69.2 - 81.3%)                  |
|  | Method A | Technician B | 57.5% (42.2 - 71.5%)   | 60.0% (52.9 - 66.7%)                    | 73.2% (66.4 - 79.0%)                  |
|  | Method B | Technician A | 55.0% (39.8 - 69.3%)   | 54.7% (47.6 - 61.6%)                    | 75.8% (69.2 - 81.3%)                  |
|  | Method B | Technician B | 52.5% (37.5 - 67.1%)   | 57.9% (50.8 - 64.7%)                    | 74.2% (67.6 - 79.9%)                  |
|  | Method C | dIFine       | 55.0% (39.8 - 69.3%)   | 57.4% (50.3 - 64.2%)                    | 67.4% (60.4 - 73.6%)                  |

**b. Clinical Performance at Site 2**

| Diagnostic Sensitivity and Specificity |          |              | % Sensitivity<br>(95% CI) | % Sensitivity<br>(95% CI)                     | % Specificity<br>(95% CI)                    |
|--|----------|--------------|---------------------------|---|--|
|  |          |              | SLE<br>(n = 40)           | CTD + ANA-Associated<br>Diseases<br>(n = 190) | Non- ANA-Associated<br>Diseases<br>(n = 160) |
| Site 2                                 | Method A | Technician A | 50.0%<br>(35.2 - 64.8%)   | 51.6%<br>(44.5 - 58.6%)                       | 83.1%<br>(76.6 - 88.1%)                      |
|  | Method A | Technician B | 55.0%<br>(39.8 - 69.3%)   | 56.3%<br>(49.2 - 63.2%)                       | 80.0%<br>(73.1 - 85.5%)                      |
|  | Method B | Technician A | 52.5%<br>(37.5 - 67.1%)   | 56.8%<br>(49.7 - 63.7%)                       | 81.3%<br>(74.5 - 86.5%)                      |
|  | Method B | Technician B | 55.0%<br>(39.8 - 69.3%)   | 58.4%<br>(51.3 - 65.2%)                       | 80.6%<br>(73.8 - 86.0%)                      |
|  | Method C | dIFine       | 52.5%<br>(37.5 - 67.1%)   | 55.8%<br>(48.7 - 62.7%)                       | 74.4%<br>(67.1 - 80.5%)                      |

**c. Clinical Performance at Site 3**

| Diagnostic Sensitivity and Specificity |          |              | % Sensitivity<br>(95% CI) | % Sensitivity<br>(95% CI)                     | % Specificity<br>(95% CI)                    |
|--|----------|--------------|---------------------------|---|--|
|  |          |              | SLE<br>(n = 40)           | CTD + ANA-Associated<br>Diseases<br>(n = 190) | Non- ANA-Associated<br>Diseases<br>(n = 190) |
| Site 3                                 | Method A | Technician A | 47.5%<br>(32.9 - 62.5%)   | 53.2%<br>(46.1 - 60.1%)                       | 76.8%<br>(70.4 - 82.3%)                      |
|  | Method A | Technician B | 55.0%<br>(39.8 - 69.3%)   | 57.4%<br>(50.3 - 64.2%)                       | 74.2%<br>(67.6 - 79.9%)                      |
|  | Method B | Technician A | 45.0%<br>(30.7 - 60.2%)   | 52.6%<br>(45.6 - 59.6%)                       | 78.9%<br>(72.6 - 84.1%)                      |
|  | Method B | Technician B | 57.5%<br>(42.2 - 71.5%)   | 56.3%<br>(49.2 - 63.2%)                       | 74.7%<br>(68.1% - 80.4%)                     |
|  | Method C | dIFine       | 55.0%<br>(39.8 - 69.3%)   | 54.2%<br>(47.1 - 61.1%)                       | 67.5%<br>(63.1 - 76.1%)                      |

Sensitivity among the SLE cohort ranged from a low of 45.0% to a high of 57.5% across all three methods, across all three sites. The prevalence of ANA observed in this SLE cohort seemed lower than what is typically observed. According to the Rheumatologists who helped with the collection of these specimens, this may be because the majority of these patients were on strong immunosuppressive treatments and either had low disease activity or were in remission. This low prevalence of ANA observed was further confirmed using another FDA-cleared, commercial ANA HEp-2 IFA product. Clinical sensitivity among the CTD + ANA-Associated Diseases cohort ranged from a low of 51.6% to a high of 60.0% across all three methods, across all three sites. Clinical specificity among the Non-ANA-Associated Diseases cohort ranged from a low of 67.4% to a high of 83.1% across all three methods, across all three sites. If one averages all methods of interpretation across all three sites, the clinical sensitivity in the SLE group averaged 53.2%, the clinical sensitivity in the CTD + ANA-Associated Diseases group averaged 55.7% and the clinical specificity in the Non-ANA-Associated Diseases group averaged 75.9%.

**4. Frequency of ANA Detected by Disease Group:**

In addition to a positive or negative determination, Method C may result in an “Uncertain” call if dIFine® could not identify the result as clearly positive or clearly negative. Uncertain results were considered negative for this summary below (i.e., were **not** positive). The table below shows the percentage of each disease category that was called qualitatively positive by each technician at each site by each method. This table summarizes the frequency of ANA found in each disease category and the consistency of that ANA determination across methods.

**Site 1:**

| Diseases                    | Technician A |          | Technician B |          | Method C |
|-----------------------------|--------------|----------|--------------|----------|----------|
|                             | Method A     | Method B | Method A     | Method B |          |
| ANA-Associated Diseases     |              |          |              |          |          |
| SLE                         | 52.5%        | 55.0%    | 57.5%        | 52.5%    | 55.0%    |
| Sjögren's                   | 50.0%        | 50.0%    | 56.7%        | 53.3%    | 53.3%    |
| Scleroderma                 | 75.0%        | 70.0%    | 80.0%        | 80.0%    | 80.0%    |
| Autoimmune Myositis         | 50.0%        | 55.0%    | 65.0%        | 60.0%    | 60.0%    |
| MCTD                        | 40.0%        | 40.0%    | 50.0%        | 55.0%    | 50.0%    |
| CREST                       | 80.0%        | 80.0%    | 80.0%        | 80.0%    | 80.0%    |
| Autoimmune Hepatitis        | 45.0%        | 50.0%    | 60.0%        | 55.0%    | 50.0%    |
| Drug-Induces Lupus          | 35.0%        | 40.0%    | 35.0%        | 35.0%    | 35.0%    |
| Non-ANA Associated Diseases |              |          |              |          |          |
| Autoimmune Thyroiditis      | 23.3%        | 16.7%    | 16.7%        | 16.7%    | 16.7%    |
| Cancer                      | 15.0%        | 15.0%    | 20.0%        | 20.0%    | 15.0%    |
| Celiac Disease              | 45.5%        | 45.5%    | 45.5%        | 45.5%    | 45.5%    |
| Crohn's Disease             | 30.0%        | 30.0%    | 30.0%        | 30.0%    | 30.0%    |
| Fibromyalgia                | 30.0%        | 40.0%    | 50.0%        | 40.0%    | 40.0%    |
| Infectious Disease          | 5.0%         | 5.0%     | 5.0%         | 5.0%     | 5.0%     |
| Inflammatory Bowel Disease  | 40.0%        | 30.0%    | 40.0%        | 20.0%    | 20.0%    |
| Rheumatoid Arthritis        | 16.7%        | 23.3%    | 23.3%        | 23.3%    | 16.7%    |
| Ulcerative Colitis          | 30.0%        | 30.0%    | 50.0%        | 60.0%    | 40.0%    |
| Vasculitis                  | 17.9%        | 14.3%    | 14.3%        | 14.3%    | 14.3%    |

**Site 2:**

| Diseases                    | Technician A |          | Technician B |          | Method C |
|-----------------------------|--------------|----------|--------------|----------|----------|
|                             | Method A     | Method B | Method A     | Method B |          |
| ANA-Associated Diseases     |              |          |              |          |          |
| SLE                         | 50.0%        | 52.5%    | 55.0%        | 55.0%    | 52.5%    |
| Sjögren's                   | 53.3%        | 53.3%    | 56.7%        | 56.7%    | 53.3%    |
| Scleroderma                 | 75.0%        | 80.0%    | 75.0%        | 80.0%    | 80.0%    |
| Autoimmune Myositis         | 55.0%        | 65.0%    | 65.0%        | 70.0%    | 60.0%    |
| MCTD                        | 30.0%        | 45.0%    | 35.0%        | 45.0%    | 45.0%    |
| CREST                       | 75.0%        | 80.0%    | 80.0%        | 80.0%    | 75.0%    |
| Autoimmune Hepatitis        | 40.0%        | 45.0%    | 45.0%        | 45.0%    | 45.0%    |
| Drug-Induces Lupus          | 35.0%        | 40.0%    | 40.0%        | 40.0%    | 40.0%    |
| Non-ANA Associated Diseases |              |          |              |          |          |
| Autoimmune Thyroiditis      | 13.3%        | 16.7%    | 16.7%        | 16.7%    | 16.7%    |
| Cancer                      | 10.0%        | 15.0%    | 15.0%        | 15.0%    | 15.0%    |
| Celiac Disease              | 20.0%        | 30.0%    | 20.0%        | 30.0%    | 30.0%    |
| Crohn's Disease             | 30.0%        | 30.0%    | 30.0%        | 30.0%    | 30.0%    |
| Fibromyalgia                | 40.0%        | 40.0%    | 40.0%        | 40.0%    | 40.0%    |
| Infectious Disease          | 5.0%         | 5.0%     | 5.0%         | 5.0%     | 5.0%     |
| Inflammatory Bowel Disease  | 20.0%        | 20.0%    | 20.0%        | 20.0%    | 20.0%    |
| Rheumatoid Arthritis        | 16.7%        | 16.7%    | 16.7%        | 16.7%    | 16.7%    |
| Ulcerative Colitis          | 40.0%        | 40.0%    | 60.0%        | 40.0%    | 40.0%    |
| Vasculitis                  | 0.0%         | 0.0%     | 10.0%        | 10.0%    | 0.0%     |

**Site 3:**

| Diseases                    | Technician A |          | Technician B |          | Method C |
|-----------------------------|--------------|----------|--------------|----------|----------|
|                             | Method A     | Method B | Method A     | Method B |          |
| ANA-Associated Diseases     |              |          |              |          |          |
| SLE                         | 47.5%        | 45.0%    | 55.0%        | 57.5%    | 52.5%    |
| Sjögren's                   | 46.7%        | 50.0%    | 60.0%        | 53.3%    | 50.0%    |
| Scleroderma                 | 75.0%        | 75.0%    | 80.0%        | 75.0%    | 75.0%    |
| Autoimmune Myositis         | 60.0%        | 60.0%    | 60.0%        | 60.0%    | 60.0%    |
| MCTD                        | 45.0%        | 45.0%    | 45.0%        | 45.0%    | 45.0%    |
| CREST                       | 80.0%        | 80.0%    | 75.0%        | 75.0%    | 75.0%    |
| Autoimmune Hepatitis        | 45.0%        | 40.0%    | 50.0%        | 50.0%    | 45.0%    |
| Drug-Induces Lupus          | 35.0%        | 35.0%    | 35.0%        | 35.0%    | 35.0%    |
| Non-ANA Associated Diseases |              |          |              |          |          |
| Autoimmune Thyroiditis      | 16.7%        | 13.3%    | 20.0%        | 16.7%    | 16.7%    |
| Cancer                      | 20.0%        | 20.0%    | 20.0%        | 25.0%    | 15.0%    |
| Celiac Disease              | 45.5%        | 45.5%    | 45.5%        | 45.5%    | 45.5%    |
| Crohn's Disease             | 30.0%        | 20.0%    | 30.0%        | 30.0%    | 30.0%    |
| Fibromyalgia                | 40.0%        | 40.0%    | 50.0%        | 50.0%    | 40.0%    |
| Infectious Disease          | 5.0%         | 5.0%     | 5.0%         | 5.0%     | 5.0%     |
| Inflammatory Bowel Disease  | 30.0%        | 30.0%    | 30.0%        | 30.0%    | 20.0%    |
| Rheumatoid Arthritis        | 23.3%        | 16.7%    | 26.7%        | 20.0%    | 16.7%    |
| Ulcerative Colitis          | 40.0%        | 40.0%    | 60.0%        | 60.0%    | 40.0%    |
| Vasculitis                  | 10.7%        | 10.7%    | 10.7%        | 14.3%    | 14.3%    |

The frequency of ANA detected in the Celiac Disease cohort seemed higher than expected. There is literature supporting elevated ANA in celiac disease patients (39). Additionally, these specimens were tested on another FDA-cleared, commercial ANA HEP-2 and the ANA was confirmed on that product.

**5. Interpretation Method Comparisons:**

There were 350 clinical samples that were tested at all three clinical sites. There were 30 additional clinically characterized celiac disease and vasculitis specimens that were tested at site one and site three. Finally, there were an additional 12 retrospectively collected specimens that exhibited the nuclear membrane or nuclear dots pattern that were tested at sites one and three. With these 392 specimens, there were a total of 2268 instances where one could compare the results of Method A versus Method B, Method A versus Method C, and Method B versus Method C. A summary of those qualitative comparisons appears in the tables below:

**a. Interpretation Method Comparisons:**

| Method A vs Method B |              | Positive Sample Agreement<br>(95% CI) | Negative Sample Agreement<br>(95% CI) | Total Sample Agreement<br>(95% CI) |
|----------------------|--------------|---------------------------------------|---------------------------------------|------------------------------------|
| Site 1               | Technician A | 95.6% (152/159)<br>(91.2 - 97.9%)     | 95.7% (223/233)<br>(92.3 - 97.7%)     | 95.7% (375/392)<br>(93.2 - 97.3%)  |
|                      | Technician B | 94.9% (168/177)<br>(90.6 - 97.3%)     | 98.6% (212/215)<br>(95.9 - 99.5%)     | 96.9% (380/392)<br>(94.7 - 98.2%)  |
| Site 2               | Technician A | 99.2% (124/125)<br>(95.6 - 99.9%)     | 93.8% (211/225)<br>(89.8 - 96.3%)     | 95.7% (335/350)<br>(93.1 - 97.4%)  |
|                      | Technician B | 98.6% (137/139)<br>(94.9 - 99.6%)     | 97.6% (206/211)<br>(94.6 - 98.95%)    | 98.0% (343/350)<br>(95.9 - 99.0%)  |
| Site 3               | Technician A | 95.5% (148/155)<br>(90.9 - 97.8%)     | 98.7% (234/237)<br>(96.4 - 99.65%)    | 97.5% (382/392)<br>(95.4 - 98.6%)  |
|                      | Technician B | 95.9% (162/169)<br>(91.7 - 97.9%)     | 97.8% (218/223)<br>(94.9 - 99.0%)     | 96.9% (380/392)<br>(94.7 - 98.2%)  |



**b. Combined Qualitative Agreement for Method A vs Method B All Sites/All Technicians**

|          |          | Method A |          |
|----------|----------|----------|----------|
|          |          | Positive | Negative |
| Method B | Positive | 891      | 40       |
|          | Negative | 33       | 1304     |

Positive Percent Agreement = 96.43% (891 / 924)      95% Confidence Interval = 95.03 - 97.45%  
 Negative Percent Agreement = 97.02% (1304 / 1344)      95% Confidence Interval = 95.97 - 97.81%  
 Total Percent Agreement = 96.78% (2195 / 2268)      95% Confidence Interval = 95.97 - 97.43%

**c. Method A vs Method C Qualitative Comparison**

Since Method C yielded uncertain results for a lot of specimens, positive and negative percent agreement was calculated using both the applicable scenarios:

**Uncertain Counted Towards Positives**

| Method A vs Method C |              | Positive Sample Agreement (95% CI) | Negative Sample Agreement (95% CI) | Total Sample Agreement (95% CI)   |
|----------------------|--------------|------------------------------------|------------------------------------|-----------------------------------|
| Site 1               | Technician A | 97.5% (155/159)<br>(93.7 - 99.0%)  | 80.3% (187/233)<br>(74.7 - 84.9%)  | 87.2% (342/392)<br>(83.6 - 90.2%) |
|                      | Technician B | 98.3% (174/177)<br>(95.1 - 99.4%)  | 87.4% (188/215)<br>(82.4 - 91.2%)  | 92.4% (362/392)<br>(89.3 - 94.6%) |
| Site 2               | Technician A | 100% (125/125)<br>(97.0 - 100.0%)  | 85.3% (192/225)<br>(80.1 - 89.4%)  | 90.6% (317/350)<br>(87.1 - 93.2%) |
|                      | Technician B | 100% (139/139)<br>(97.3 - 100.0%)  | 91.0% (192/211)<br>(86.4 - 94.2%)  | 94.6% (331/350)<br>(91.7 - 96.5%) |
| Site 3               | Technician A | 100% (155/155)<br>(97.6 - 100.0%)  | 87% (206/237)<br>(82.0 - 90.7%)    | 92.1% (361/392)<br>(88.9 - 94.4%) |
|                      | Technician B | 98.8% (167/169)<br>(95.8 - 99.7%)  | 91.9% (205/223)<br>(87.6 - 94.8%)  | 94.9% (372/392)<br>(92.3 - 96.7%) |

**d. Results for Method A vs Method C for all sites and all technicians combined presented below:**

|          |          | Method A |          |
|----------|----------|----------|----------|
|          |          | Positive | Negative |
| Method C | Positive | 915      | 174      |
|          | Negative | 9        | 1170     |

Positive Percent Agreement: 99.03 % (915/924)      95% CI: 98.39 - 99.55%  
 Negative Percent Agreement: 87.05 % (1170/1344)      95% CI: 85.15 - 88.74%  
 Total Percent Agreement: 91.93 % (2085/2268)      95% CI: 90.74 - 92.98%

**Uncertain Counted Towards Negatives**

| Method A vs Method C |              | Positive Sample Agreement (95% CI) | Negative Sample Agreement (95% CI) | Total Sample Agreement (95% CI)   |
|----------------------|--------------|------------------------------------|------------------------------------|-----------------------------------|
| Site 1               | Technician A | 93.1% (148/159)<br>(88.0 - 96.1%)  | 94.0% (219/233)<br>(90.2 - 96.4%)  | 93.6% (367/392)<br>(90.8 - 96.5%) |
|                      | Technician B | 90.4% (160/177)<br>(85.2 - 93.9%)  | 99.1% (213/215)<br>(96.7 - 99.7%)  | 95.2% (373/392)<br>(92.6 - 96.9%) |
| Site 2               | Technician A | 99.2% (124/125)<br>(95.1 - 99.9%)  | 94.7% (213/225)<br>(90.9 - 96.9%)  | 96.3% (337/350)<br>(93.8 - 97.8%) |
|                      | Technician B | 95.0% (132/139)<br>(89.9 - 97.5%)  | 98.1% (207/211)<br>(95.2 - 99.3%)  | 96.9% (339/350)<br>(94.5 - 98.2%) |
| Site 3               | Technician A | 96.1% (149/155)<br>(91.8 - 98.2%)  | 97.1% (230/237)<br>(94.4 - 98.1%)  | 96.7% (379/392)<br>(94.4 - 98.1%) |
|                      | Technician B | 90.5% (153/169)<br>(85.2 - 94.1%)  | 98.7% (220/223)<br>(96.1 - 99.5%)  | 95.2% (373/392)<br>(92.6 - 96.9%) |

**e. Results for Method A vs Method C for all sites and all technicians combined presented below:**

|          |          | Method A |          |
|----------|----------|----------|----------|
|          |          | Positive | Negative |
| Method C | Positive | 866      | 42       |
|          | Negative | 58       | 1302     |

Positive Percent Agreement: 93.72 % (866/924)      95% CI: 91.97 - 95.11%  
 Negative Percent Agreement: 96.88% (1302/1344)      95% CI: 95.80 - 97.68%  
 Total Percent Agreement: 95.59 % (2168/2268)      95% CI: 94.67 - 96.36%

**f. Method B vs Method C Qualitative Comparison**

Since Method C can yield an uncertain (UNC) result in addition to a positive or negative qualitative result, the agreement between methods were calculated using the UNC samples considered positive and then considered negative:

**UNC considered as positive for each site and each technician.**

| Method B vs Method C |              | Positive Sample Agreement (95% CI)  | Negative Sample Agreement (95% CI) | Total Sample Agreement (95% CI)   |
|----------------------|--------------|-------------------------------------|------------------------------------|-----------------------------------|
| Site 1               | Technician A | 100.0% (162/162)<br>(97.7 - 100.0%) | 83.0% (191/230)<br>(77.7 - 87.3%)  | 90.1% (353/392)<br>(86.7 - 92.7%) |
|                      | Technician B | 99.4% (170/171)<br>(96.8 - 99.9%)   | 86.4% (191/221)<br>(81.3 - 90.3%)  | 91.8% (360/392)<br>(88.7 - 94.2%) |
| Site 2               | Technician A | 100.0% (138/138)<br>(97.3 - 100.0%) | 90.6% (192/212)<br>(85.9 - 93.8%)  | 94.3% (330/350)<br>(91.3 - 96.3%) |
|                      | Technician B | 100.0% (142/142)<br>(97.4 - 100.0%) | 92.3% (192/208)<br>(87.9 - 95.2%)  | 95.4% (334/350)<br>(92.7 - 97.2%) |
| Site 3               | Technician A | 99.3% (150/151)<br>(96.3 - 99.9%)   | 85.5% (206/241)<br>(80.5 - 89.4%)  | 89.9% (356/392)<br>(86.5 - 92.5%) |
|                      | Technician B | 99.4% (166/167)<br>(96.7 - 99.9%)   | 91.6% (206/225)<br>(87.2 - 94.5%)  | 94.9% (372/392)<br>(92.3 - 96.7%) |

**Combined Qualitative Agreement Between Method B and Method C for All Sites/All Technicians (UNC as Positives):**

|          |          | Method B |          | Total |
|----------|----------|----------|----------|-------|
|          |          | Positive | Negative |       |
| Method C | Positive | 928      | 160      | 1088  |
|          | Negative | 3        | 1177     | 1180  |
|          | Total    | 931      | 1337     | 2268  |

Positive Percent Agreement: 99.7 % (928/931)      95% CI: 99.1 - 99.9%  
 Negative Percent Agreement: 88.0 % (1177/1337)      95% CI: 86.2 - 89.7%  
 Total Percent Agreement: 92.8% (2105/2268)      95% CI: 91.7 - 93.8%

**UNC Considered as Negative for Each Site and Each Technician**

| Method B vs Method C |              | Positive Sample Agreement (95% CI) | Negative Sample Agreement (95% CI)   | Total Sample Agreement (95% CI)    |
|----------------------|--------------|------------------------------------|--------------------------------------|------------------------------------|
| Site 1               | Technician A | 95.7% (155/162)<br>(91.4 - 97.9%)  | 97.0% (223/230)<br>(93.9 - 98.5%)    | 96.4% (378/392)<br>(94.1 - 97.9%)  |
|                      | Technician B | 94.2% (161/171)<br>(89.6 - 96.8%)  | 99.6% (220/221)<br>(97.5 - 99.9%)    | 97.2% (381/392)<br>(95.1 - 98.4%)  |
| Site 2               | Technician A | 98.6% (136/138)<br>(94.9 - 99.60%) | 100.0% (212/212)<br>(98.2 - 100.0%)  | 99.4% (348/350)<br>(97.9 - 99.8%)  |
|                      | Technician B | 95.8% (136/142)<br>(91.1 - 98.1%)  | 100.00% (208/208)<br>(98.2 - 100.0%) | 98.3% (344/350)<br>(96.3 - 99.2%)  |
| Site 3               | Technician A | 98.0% (148/151)<br>(94.3 - 99.3%)  | 96.7% (233/241)<br>(93.6 - 98.3%)    | 97.2% (381/392)<br>(95.1 - 98.4%)  |
|                      | Technician B | 92.8% (155/167)<br>(87.9 - 95.8%)  | 99.56% (224/225)<br>(97.5 - 99.9%)   | 96.68% (379/392)<br>(94.4 - 98.1%) |

**Combined Qualitative Agreement Between Method B and Method C for All Sites/All Technicians (UNC as Negatives):**

|          |          | Method B |          | Total |
|----------|----------|----------|----------|-------|
|          |          | Positive | Negative |       |
| Method C | Positive | 891      | 17       | 908   |
|          | Negative | 40       | 1320     | 1360  |
| Total    |          | 931      | 1337     | 2268  |

Positive Percent Agreement: 95.7% (891/931)      95% CI: 94.2 - 96.8%  
 Negative Percent Agreement: 98.7% (1320/1337)      95% CI: 98.0 - 99.2%  
 Total Percent Agreement: 97.5% (2211/2268)      95% CI: 96.8 - 98.1%

In all cases, the qualitative agreement between interpretation methods is quite high indicating that all three methods (manual microscope, digital read of the diFine® scanner and automated call from the diFine® scanner) correlate well with each other and exhibited few discrepancies.

Additionally, pattern determinations were correlated across different interpretation methods; samples that had no pattern (i.e., 'negative') or samples that yielded uncertain results (i.e., 'UNC') were included in the pattern agreement analyses between the different interpretation methods are presented in the table below:

|        |              | Method A vs Method B                                   | Method A vs Method C                                   | Method B vs Method C                                   |
|--------|--------------|--|--|--|
|        |              | Percent Agreement (%)<br>(# Agree/Total #)<br>[95% CI] | Percent Agreement (%)<br>(# Agree/Total #)<br>[95% CI] | Percent Agreement (%)<br>(# Agree/Total #)<br>[95% CI] |
| Site 1 | Technician A | 98.5<br>(386/392)<br>[96.7 - 99.3%]                    | 84.2<br>(330/392)<br>[80.2 - 87.5%]                    | 83.9<br>(329/392)<br>[80.0 - 87.2%]                    |
|        | Technician B | 97.7<br>(383/392)<br>[95.7 - 98.8%]                    | 85.0<br>(333/392)<br>[81.1 - 88.2%]                    | 85.2<br>(334/392)<br>[81.4 - 88.4%]                    |
| Site 2 | Technician A | 96.9<br>(339/350)<br>[94.5 - 98.2%]                    | 86.0<br>(301/350)<br>[82.0 - 89.3%]                    | 86.9<br>(304/350)<br>[82.9 - 90.0%]                    |
|        | Technician B | 97.7<br>(342/350)<br>[95.6 - 98.8%]                    | 86.6<br>(303/350)<br>[82.6 - 89.8%]                    | 87.1<br>(305/350)<br>[83.2 - 90.3%]                    |
| Site 3 | Technician A | 98.47<br>(386/392)<br>[96.7 - 99.3%]                   | 88.3<br>(346/392)<br>[84.7 - 91.1%]                    | 88.5<br>(347-392)<br>[85.0 - 91.3%]                    |
|        | Technician B | 98.2<br>(385/392)<br>[96.4 - 99.1%]                    | 88.0<br>(345/392)<br>[84.4 - 90.9%]                    | 87.5<br>(343/392)<br>[83.9 - 90.4%]                    |

Combining all three sites together resulted in the following pattern agreement:

|                      | Pattern Agreement Number/Total Samples | Percent Agreement (%) | 95% CI     |
|----------------------|--|-----------------------|------------|
| Method A vs Method B | 2221/2268                              | 98.0                  | 97.3-98.4% |
| Method A vs Method C | 1958/2268                              | 86.3                  | 84.9-87.7% |
| Method B vs Method C | 1962/2268                              | 86.5                  | 85.0-87.9% |

Samples that were positive by any method at each site were titrated to endpoint and interpreted by all three methods. Samples that were qualitatively positive by all three methods at any one site could be compared for endpoint agreement. At site one, there were 156 specimens titrated to endpoint. At site two there were 133 specimens titrated to endpoint and at site three there were 154 specimens titrated to endpoint. Considering there were two technicians at each site to read by both method A and method B, this resulted in 886 times comparisons in endpoint determinations could be made between Method A versus Method B, Method A versus Method C and Method B versus Method C. The number of times those endpoint determinations matched each other plus or minus one, two-fold dilution is depicted in the table below:

| Combined Endpoint Titer Agreement (All Sites/All Technicians) |                              |                       |                |
|---|------------------------------|-----------------------|----------------|
| Interpretation  | [± 1 dilution]/Total Samples | Percent Agreement (%) | 95% CI         |
| Method A vs. Method B   | 880/886                      | 99.32                 | 98.53 - 99.69% |
| Method A vs. Method C   | 879/886                      | 99.21                 | 98.38 - 99.62% |
| Method B vs. Method C   | 880/886                      | 99.32                 | 98.53 - 99.69% |

This comparison shows that the endpoint determination between methods is high and there were very few instances where the endpoint dilution determined by one method resulted in an endpoint dilution that was greater than  $\pm$  one dilution by another method.





















Taken altogether, these data demonstrate that the auto-call pattern identified by diFine® (Method C) agrees with Method A and/or Method B (non-automated pattern identification methods) for most of the samples. However, it is still the responsibility of the trained operator to make the final decision.

## REFERENCES

1. Barnett EV: Mayo. Clin. Proc. 44:645, 1969.
2. Burnham TK, Fine G, Neblett TR: Ann. Int. Med. 63:9, 1966.
3. Casals SP, Friou GJ, Meyers LL: Arthritis Rheum. 7:379, 1964.
4. Condemi JJ, Barnett EV, Atwater EC, *et al*: Arthritis Rheum. 8:1080, 1965.
5. Dorsch CA, Gibbs CB, Stevens MB, Shelman LE: Ann. Rheum. Dis. 28:313, 1969.
6. Dubois EL: J. Rheum. 2:204, 1975.
7. Alarcon-Segovia D, Fishbein E: J. Rheum. 2:167, 1975.
8. Friou GJ: J. Clin. Invest. 36:890, 1957.
9. Friou GJ, Finch SC, Detre KD: J. Immunol. 80:324, 1958.
10. Coons AH, Creech H, Jones RN, *et al*: J. Immunol. 80:324, 1958.
11. Barnett EV, North AF, Condemi JJ, Jacox RF, Vaughn JH: Ann. Intern. Med. 63:100, 1965.
12. Lachman PJ, Kunkel HG: Lancet 2:436, 1961.
13. Friou GJ: Arthritis Rheum. 7:161, 1964.
14. Beck JS: Scot. Med. J. 8:373, 1963.
15. Anderson JR, Gray KG, Beck JS, *et al*: Ann. Rheum. Dis. 21:360, 1962.
16. Luciano A, Rothfield NF: Ann. Rheum. Dis. 32:337, 1973.
17. Harmon C, Deng JS, Peebles CL, *et al*: The importance of tissue substrate in the SS-A/Ro antigen-antibody system. Arthritis Rheum. 27:166-173, 1984.
18. Peebles CL, Molden DP, Klipple GL, Nakamura RM: An antibody to histone H3 which produces a variable large speckled (VLS) immunofluorescent pattern on mouse kidney. Arthritis Rheum. 27:S44, 1984.
19. Ritchie RF: Antinuclear antibodies: Their frequency and diagnostic association. N. Engl. J. Med. 282:1174-1178, 1970.
20. Deng JS, Sontheimer RD, Gilliam JN: Relationships between antinuclear and anti-Ro/SS-A antibodies in subacute cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 11:494-499, 1984.
21. Meyer O, Hauptmann G, Tappeiner G, Ochs HD, Mascart-Lemone F: Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro(SSA) antibodies. Clin. Exp. Immunol. 62:678-684, 1985.
22. Provost TT, Arnett FC, Reichlin M: Homozygous C2 deficiency, lupus erythematosus and anti-Ro(SS-A) antibodies. Arthritis Rheum. 26:1279-1282, 1983.
23. Speirs C, Fielder AHL, Chapel H, *et al*: Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1:922-924, 1989.
24. Watson RM, Scheel JN, Petri M, *et al*: Neonatal lupus erythematosus syndrome: Analysis of C4 allotypes and C4 genes in 18 families. Medicine 71:84-95, 1992.
25. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C: Arthritis Rheum. Vol. 23 No. 6:617, 1980.
26. Hall AP, Bardawil WA, Bayles TB, *et al*: N. Engl. J. Med. 263:769, 1960.
27. Pollack VE: N. Engl. J. Med. 271:165, 1964.
28. Raskin J: Arch. Derm. 89:569, 1964.
29. Beck JS, Anderson JR, Gray KG, Rowell NR: Lancet 2:1188, 1963.
30. Procedures for the collection of diagnostic blood specimens by venipuncture - Second edition; Approved Standard (1984). Published by the National Committee for Clinical Laboratory Standards.
31. Procedures for the Handling and Processing of Blood Specimens. NCCLS Document H18-A, Vol. 10, No. 12, Approved Guideline, 1990.
32. Beck JS: Lancet, 1:1203, 1961.
33. Sharp GC, Irvin WS, Tan EM, *et al*: Am. J. Med. 52:48, 1972.
34. Burnham TK, Neblett TR, Fine G: Am. J. Clin. Path. 50:683, 1968.
35. Textbook of Immunopathology, Vol II, P Miescher and HJ Muller-Eberhard (Eds), Glune & Stratton, NY, 1969.
36. Wittingham S, Irvin J, Mackay IR, *et al*: Aust. Ann. Med. 18:130, 1969.
37. U.S. Department of Labor, Occupational Safety and Health Administration: Occupational Exposure to Bloodborne Pathogens, Final Rule. Fed. Register 56:64175-64182, 1991.
38. Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests; Approved Guidelines - 4<sup>th</sup> Edition (2010). CLSI Document GP44-A4 (ISBN 1-56238-724-3). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087.
39. Barton, S., Murray, J., Gastroenterol Clin North Am. 2008 June ; 37(2): 411-vii. doi:10.1016/j.gtc.2008.02.001

### GLOSSARY OF SYMBOLS

The following symbols **may** have been used in the labelling of this product.

| Symbol  | Description                               | Symbol   | Description                     |
|---|---|--|---------------------------------|
|    | Manufacturer                              |     | Keep away from sunlight         |
|    | <i>In vitro</i> diagnostic medical device |     | Conformity with Directive 98/79 |
|    | Catalogue number                          |    | Cover Glass                     |
|    | Sufficient for <i>n</i> tests             |    | Substrate Slide                 |
|    | Batch code                                |    | PBS Buffer                      |
|    | Use by                                    |    | Mounting Media                  |
|    | Storage Temperature limitations           |    | Conjugate                       |
|   | For Prescription Use Only                 |   | Positive Control                |
|  | Consult electronic instructions for use   |  | Negative Control                |
|  | Store in the upright position             |  | Made in the USA                 |



#### ZEUS Scientific

200 Evans Way, Branchburg, New Jersey, 08876, USA  
 Toll Free (U.S.): 1-800-286-2111, Option 2  
 International: +1 908-526-3744  
 Fax: +1 908-526-2058  
 Website: [www.zeusscientific.com](http://www.zeusscientific.com)

For US Customer Service contact your local distributor.  
 For US Technical Support contact ZEUS Scientific, call toll free or e-mail [support@zeusscientific.com](mailto:support@zeusscientific.com).  
 For Non-US Customer Service and Technical Support inquiries, please contact your local distributor.  
**\*2019 ZEUS Scientific. All Rights Reserved.**



EMERGO EUROPE  
 Westervoortsedijk 60  
 6827 AT Arnhem  
 The Netherlands